Safety Advantages of Tab-Cel Over Other T-Cell Therapies in EBV+ PTLD
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.
Tablecleucel (tab-cel; Atara Biotherapeutics) yielded clinically meaningful improvements in overall response rate (ORR) with promising overall survival (OS) rates in patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).1,2
These data, from the phase 3 ALLELE study (NCT03394365), were presented at the
The ALLELE study has enrolled 38 evaluable, heavily pretreated patients with EBV+ PTLD as of May 2021. Independent objective response rate was 50% (95% CI [33.4, 66.6]; n = 19) with tab-cel treatment. Median duration of response is promising but cannot yet be assessed. Investigators observed no new safety signals or concerns, and safety findings were consistent with previously published data.
GeneTherapyLive spoke with AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, to learn more about the safety findings of tab-cel and how they compare to those of other T-cell therapies, including chimeric antigen receptor (CAR) T-cell therapies. He also discussed extended data with tab-cel for up to 20 years from clinical experience at MSK.
For more coverage of ASH 2021,
REFERENCES
1. Atara Biotherapeutics to present eight abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, including first presentation of Tab-cel® pivotal phase 3 (ALLELE) data. News release. Atara Biotherapeutics. November 4, 2021. https://www.businesswire.com/news/home/20211104005811/en/Atara-Biotherapeutics-to-Present-Eight-Abstracts-at-the-63rd-American-Society-of-Hematology-ASH-Annual-Meeting-Including-First-Presentation-of-Tab-cel%C2%AE-Pivotal-Phase-3-ALLELE-Data
2. Prockop S, Mahadeo KM, Beitinjaneh A, et al. Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 301.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025